ClinicalTrials.gg
Enrolling by invitationNCT05199870Updated Mar 19, 2026

MDR - PMCF Study for RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads

An observational study in Hip Arthritis, Hip Disease and Hip Fractures, sponsored by Zimmer Biomet. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Zimmer Biomet · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
116
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Hip Fractures by Zimmer Biomet — 5 open to participants now, 8 under way, none of them phase 3. Hip Fractures · Zimmer Biomet.

Planned enrollment
7th of 11
116 · median 149
Started
2026
with 1 other
Observational
11 of 16
3 open now
Registered
12th of 16
by date

Among the 16 studies in Hip Fractures by Zimmer Biomet, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2026, is one of 11 observational ones, and was the 12th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

5 of the 16 studies in Hip Fractures by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hip Fractures by Zimmer Biomet, or all of them as a file.
02

Study summary

The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and the Endo II Femoral Head when used for hip hemiarthroplasty (implants and instrumentation).

Read the detailed description

The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and the Endo II Femoral Head when used for hip hemiarthroplasty (implants and instrumentation).

The primary objective of this study is the assessment of safety by analyzing implant survivorship at the longest follow-up timepoint available, greater than or equal to eight years post-implantation. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relationship of the events to implant, instrumentation and/or procedure should be specified.

The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).

03

Conditions studied

  • Hip Arthritis
  • Hip Disease
  • Hip Fractures
  • Hip Injuries
  • Hip Pain Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A consecutive series of patients implanted with the RingLoc Bipolar acetabular cup or the Endo II Femoral Head.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 years of age or older and skeletally mature
  • Patient must have undergone hip hemiarthroplasty surgery with the RingLoc Bipolar Acetabular Cup or Endo II Femoral Head for a cleared indication, greater than or equal to eight years previous to the date of study consent. Cleared indications for the RingLoc Bipolar and Endo II Heads include the following:

    • Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
    • Rheumatoid arthritis
    • Correction of functional deformity
    • Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.

Exclusion criteria

Exclusion Criteria:

  • Any medical diagnosis present at the time of surgery that, at the Investigator's discretion, could compromise the implant's survivability
  • Off-label use or not according to the approved instructions for use (IFU) of study devices
  • Revision procedures where other treatment or devices have failed
  • Uncooperative patient or patient with neurologic disorders who is incapable of following directions
  • Patient has a psychiatric illness or
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
116 participants (estimated)
Patient registry
No

Groups and cohorts

  • RingLoc Bipolar Acetabular Cup

    Patients that have been implanted with the RingLoc Bipolar acetabular cup to repair hip malfunction/disease/injury.

    Device: RingLoc Bipolar Acetabular Cup

  • Endo II Femoral Heads

    Subjects who were implanted with the Endo II Femoral head during hemiarthroplasty

    Device: Endo II Femoral Head

Interventions

  • DeviceRingLoc Bipolar Acetabular Cup

    Patients that have been implanted with a RingLoc Bipolar acetabular cup.

  • DeviceEndo II Femoral Head

    Subjects that have been implanted with an Endo II Femoral Head

06

What researchers measure

Primary outcomes

  1. Device safety assessed through the frequency and incidence of revisions, complications, and Adverse Events.

    The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and Adverse Events. Relation of the events to either implant or instrumentation will be specified.

    Time frame: Greater than or equal to 8 years.

Secondary outcomes

  1. Device Performance and Benefits evaluated through the Oxford Hip Score and Patient Assessment.

    The OHS is a patient-completed, 12-question evaluation. Each item is scored from 1 to 5, with 1 representing best outcome/least symptoms and 5 representing worst outcome/most symptoms. The Patient Assessment is patient completed and a 4-question evaluation.

    Time frame: Greater than or equal to 8 years.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 124 observational studies under Hip Fractures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 83. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 20, 2022
StartActual
Mar 10, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05199870
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Mar 10, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Lynsey Boyle
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion